Nektar Therapeutics Files 8-K Report
Ticker: NKTR · Form: 8-K · Filed: Jun 24, 2025 · CIK: 906709
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: NKTR
TL;DR
Nektar Therapeutics filed an 8-K. Check for updates.
AI Summary
On June 24, 2025, Nektar Therapeutics filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Nektar Therapeutics is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific details of material events or financial changes.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- June 24, 2025 (date) — Date of earliest event reported
- 455 Mission Bay Boulevard South (address) — Principal Executive Offices
- San Francisco, California 94158 (address) — Principal Executive Offices
FAQ
What specific event triggered this 8-K filing?
The filing indicates it is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, but the specific triggering event is not detailed in the provided excerpt.
When was the earliest event reported in this filing?
The earliest event reported was on June 24, 2025.
What is Nektar Therapeutics' principal executive office address?
Nektar Therapeutics' principal executive offices are located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is Nektar Therapeutics' IRS Employer Identification Number?
Nektar Therapeutics' IRS Employer Identification Number is 94-3134940.
What is the Commission File Number for Nektar Therapeutics?
The Commission File Number for Nektar Therapeutics is 0-24006.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 24, 2025 regarding NEKTAR THERAPEUTICS (NKTR).